Review

Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies

  1. Christoph Krisp1,2,
  2. Sarah A. Randall1,
  3. Matthew J. McKay1,3,
  4. Mark P. Molloy1,3,*

Article first published online: 27 DEC 2011

DOI: 10.1002/prca.201100062

Issue

PROTEOMICS - Clinical Applications

PROTEOMICS - Clinical Applications

Volume 6, Issue 1-2, pages 42–59, January 2012

Additional Information

How to Cite

Krisp, C., Randall, S. A., McKay, M. J. and Molloy, M. P. (2012), Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies. Prot. Clin. Appl., 6: 42–59. doi: 10.1002/prca.201100062

Author Information

  1. 1

    Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, Australia

  2. 2

    Faculty of Chemistry and Biochemistry, Department of Analytical Chemistry, Ruhr-University Bochum, Bochum, Germany

  3. 3

    Australian Proteome Analysis Facility (APAF), Macquarie University, Sydney, Australia

*APAF, Macquarie University, Sydney 2109, Australia Fax: +612-9850-6200

Publication History

  1. Issue published online: 24 MAR 2012
  2. Article first published online: 27 DEC 2011
  3. Manuscript Accepted: 25 OCT 2011
  4. Manuscript Revised: 21 OCT 2011
  5. Manuscript Received: 15 JUL 2011

Funded by

  • Cancer Institute NSW

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (201K)

Keywords:

  • Biomarker;
  • Plasma;
  • Protein;
  • Selected reaction monitoring;
  • Quantitation

Abstract

The widespread clinical adoption of protein biomarkers with diagnostic, prognostic and/or predictive value remains a formidable challenge for the biomedical community. From discovery to validation, the path to biomarkers of clinical relevance abounds with many protein candidates, yet so few concrete examples have been substantiated. In this review, we focus on the recent adoption of selected reaction monitoring (SRM) of plasma proteins in the path to clinical use for a broad range of diseases including cancer, cardiovascular disease, genetic disorders and various metabolic disorders. Recent progress reveals a promising outlook for clinical applications using SRM, which now provides the routine analysis of clinically relevant protein markers at low nanogram per millilitre in plasma.

Get PDF (201K)